Poor Reliability of Therapeutic Drug Monitoring Data for Haloperidol and Bromperidol Using Enzyme Immunoassay

Therapeutic Drug Monitoring

Volumn 25, Issue 6, 2003, Pages 709-714

  Yasui Furukori, Norio ^a   Furukori, Hanako ^a,b   Saito, Manabu ^a,c   Inoue, Yoshimasa ^d   Kaneko, Sunao ^a   Tateishi, Tomonori ^a  

^a HIROSAKI UNIVERSITY   (Japan)

^b Department of Psychiatry   (Japan)

^c Hirosaki Aiseikai Hospital   (Japan)

^d Mitsubishi Pharma   (Japan)

Author keywords

Bromperidol; EIA; Haloperidol; HPLC; Reduced metabolites

Indexed keywords

ALPRAZOLAM; ANTICONVULSIVE AGENT; ANTIPARKINSON AGENT; BIPERIDEN; BROMPERIDOL; BROTIZOLAM; CARBAMAZEPINE; CHLORPROMAZINE; DIAZEPAM; FLUNITRAZEPAM; HALOPERIDOL; HYPNOTIC AGENT; LEVOMEPROMAZINE; LITHIUM; MOPERONE; NITRAZEPAM; PIPAMPERONE; QUAZEPAM; QUETIAPINE; RISPERIDONE; SPIPERONE; SULPIRIDE; THIORIDAZINE; TIMIPERONE; ZOTEPINE;

ACCURACY; ADULT; AGED; ARTICLE; DRUG BLOOD LEVEL; DRUG MONITORING; ENZYME IMMUNOASSAY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RELIABILITY; SCHIZOPHRENIA;

ADULT; AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG MONITORING; FEMALE; HALOPERIDOL; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; REAGENT KITS, DIAGNOSTIC;

EID: 0345492319     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200312000-00009     Document Type: Article

References (20)

1. Tsang MW, Shader RI, Greenblatt DJ. Metabolism of haloperidol: clinical implications and unanswered questions. J Clin Psychopharmacol. 1994;14:159-162.
2. Van Putten T, Marder SR, Mintz J, et al. Haloperidol plasma levels and clinical response: a therapeutic window relationship. Am J Psychiatry. 1992; 149: 500-505.
3. Pöldinger W, Bures E, Haage H. Double-blind study with two butyrophenone derivatives: bromperidol vs haloperidol. Int Pharmacopsychiatry. 1977;12: 184-192.
4. Malfroid M, Hens L, Roosen P, et al. Double-blind evaluation of bromperidol versus haloperidol treatment in chronic psychotic patients. Acta Psychiatr Belg. 1978;78:147-154.
5. Woggon B. Effects and side-effects of bromperidol in comparison with other antipsychotic drugs. Acta Psychiatr Belg. 1978;78:155-172.
6. Yasui-Furukori N, Kondo T, Ishida M, et al. Therapeutic effects of bromperidol on the five dimensions of schizophrenic symptoms. Prog Neuropsychopharmacol. Biol Psychiatry. 2002;26:53-57.
7. Someya T, Muratake T, Hirokane G, et al. Interindividual variation in bromperidol metabolism and relationship to therapeutic effects. J Clin Psychopharmacol. 2000;20:175-180.
8. The American Psychiatric Association. Diagnostic and Statistical Manual for Mental Disorders, 4th ed. Washington, DC, The American Psychiatric Association, 1994.
9. Hikida K, Inoue Y, Miyazaki T, et al. Determination of bromperidol in serum by automated column-switching high-performance liquid chromatography. J Chromatogr. 1989;495:227-234.
10. Lane HY, Chang WH, Chang YC, et al. Dose-dependent reduced haloperidol/haloperidol ratios: influence of patient-related variables. Psychiatry Res. 1997;72:127-132.
11. Chang WH, Hwu HG, Lane HY, et al. Dose-dependent reduced haloperidol/haloperidol ratios in schizophrenic patients. Psychiatry Res. 1991;38: 215-225.
12. Lam YW, Chang WH, Jann MW, et al. Interindividual variabilities in haloperidol interconversion and the reduced haloperidol/haloperidol ratio. Neuropsychopharmacology. 1992;7:33-39.
13. Chang WH. Reduced haloperidol: a factor in determining the therapeutic benefit of haloperidol treatment? Psychopharmacology (Berl). 1992;106:289-296.
14. Fang J, Yu PH. Effect of haloperidol and its metabolites on dopamine and noradrenaline uptake in rat brain slices. Psychopharmacology (Berl). 1995;121: 379-384.
15. Lane HY, Lin HN, Hu OY, et al. Blood levels of reduced haloperidol versus clinical efficacy and extra-pyramidal side effects of haloperidol. Prog Neuropsychopharmacol Biol Psychiatry. 1997;21:299-311.
16. Yasui N, Kondo T, Otani K, et al. Prolactin response to bromperidol treatment in schizophrenic patients. Pharmacol Toxicol. 1998;82:153-156.
17. Hirokane G, Someya T, Takahashi S, et al. Interindividual variation of plasma haloperidol concentrations and the impact of concomitant medications: the analysis of therapeutic drug, monitoring data. Ther Drug Monit. 1999;21:82-86.
18. Shimoda K, Someya T, Morita S, et al. Lower plasma levels of haloperidol in smoking than in nonsmoking schizophrenic patients. Ther Drug Monit. 1999;21: 293-296.
19. Shimoda K, Morita S, Yokono A, et al. CYP2D6*10 alleles are not the determinant of the plasma haloperidol concentrations in Asian patients. Ther Drug Monit. 2000;22:392-396.
20. Fukuda R. Factors affecting serum haloperidol level assessed by longitudinal therapeutic monitoring. Prog Neuropsychopharmacol Biol Psychiatry. 2000;24:1299-1318.